Mass General Brigham receives $50M gift for gene and cell therapy research

Letai announces: NCI met FY26 goal of full funding payout

In a post on NCI’s LinkedIn, NCI Director Anthony Letai confirmed that the institute has fully awarded and paid out all of its grant funding for the Fiscal Year 2026.

October 16, 2026

Vol.52 No.38

By Claire Marie Porter

In Brief

Moffitt advances patient avatar technologies through $15M federal research initiative

Moffitt Cancer Center is advancing patient avatar technologies through a $15 million federally funded research initiative in collaboration with the Murtha Cancer Center Research Program at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.

October 16, 2026

Vol.52 No.38

Podcast

Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

October 07, 2026

Funding Opportunities

Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research

Cancer Grand Challenges has launched two new targeted challenges focused on gastroesophageal cancer, with awards of up to $34 million available through support from the Torrey Coast Foundation and Cancer Research UK.

September 25, 2026

Vol.52 No.35

Clinical Roundup

COA survey finds high bispecific therapy adoption among community oncology practices

The Community Oncology Alliance announced results from a national survey examining how independent community oncology practices deliver bispecific therapies on Sept. 22.

September 25, 2026

Vol.52 No.35

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.

September 18, 2026

Vol.52 No.34

By Jeff Sorenson

Mass General Brigham receives $50M gift for gene and cell therapy research

YOU MAY BE INTERESTED IN

Letai announces: NCI met FY26 goal of full funding payout

Moffitt advances patient avatar technologies through $15M federal research initiative

Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”

Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research

COA survey finds high bispecific therapy adoption among community oncology practices

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Renew today!

Subscriber content

Never miss an issue!

Login

Mass General Brigham receives $50M gift for gene and cell therapy research

YOU MAY BE INTERESTED IN

Letai announces: NCI met FY26 goal of full funding payout

Moffitt advances patient avatar technologies through $15M federal research initiative

Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”

Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research

COA survey finds high bispecific therapy adoption among community oncology practices

The end of “more money, more people, more trials”Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Never miss an issue!

Login

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.